Citations (29)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Zhong Yuan, Frank DeFalco, Lu Wang, Laura Hester, James Weaver, Joel N. Swerdel, Amy Freedman, Patrick Ryan, Martijn Schuemie, Rose Qiu, Jacqueline Yee, Gary Meininger, Jesse A. Berlin & Norman Rosenthal. (2020) Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. Current Medical Research and Opinion 36:7, pages 1117-1124.
Read now
Read now
María Molina-Vega, Araceli Muñoz-Garach, José C. Fernández-García & Francisco J. Tinahones. (2018) The safety of DPP-4 inhibitor and SGLT2 inhibitor combination therapies. Expert Opinion on Drug Safety 17:8, pages 815-824.
Read now
Read now
Articles from other publishers (27)
Munaza Riaz, Jingchuan Guo, Steven M. Smith, Eric A. Dietrich, David E. Winchester & Haesuk Park. (2024) Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study. American Journal of Cardiovascular Drugs 24:3, pages 455-464.
Crossref
Crossref
Mustafa Tanrıverdi, Mehmet Baştemir, Hadiye Demirbakan, Alperen Ünalan, Merve Türkmen & Gülşen Özkan Tanrıverdi. (2023) Association of SGLT-2 inhibitors with bacterial urinary tract infection in type 2 diabetes. BMC Endocrine Disorders 23:1.
Crossref
Crossref
Michael Kelly, Jelena Lewis, Hindu Rao, Jessica Carter, Ivan Portillo & Richard Beuttler. (2022)
Effects of
GLP
‐1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta‐analysis
. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 42:12, pages 921-928.
Crossref
Crossref
Sanobia Yousuf & Muhammad Yakoob Ahmedani. (2022) Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 16:11, pages 102633.
Crossref
Crossref
Max Egers & Marijane Hynes. (2022) Sodium-glucose co-transporter 2 inhibitors in 2022: mechanisms of cardiorenal benefit. Journal of Kidney Care 7:5, pages 216-224.
Crossref
Crossref
Louise Gek Huang Goh, Jiandong Sun, Benjamin Shao Kiat Ong, Daphne Khoo, Chee Fang Sum & Kwong Ng. (2022) Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study. Journal of Diabetes & Metabolic Disorders 21:1, pages 521-555.
Crossref
Crossref
Huayang Li, Yitao Zhang, Shunjun Wang, Yuan Yue, Quan Liu, Suiqing Huang, Huajing Peng, Yi Zhang, Weijie Zeng & Zhongkai Wu. (2021) Dapagliflozin has No Protective Effect on Experimental Pulmonary Arterial Hypertension and Pulmonary Trunk Banding Rat Models. Frontiers in Pharmacology 12.
Crossref
Crossref
N. V. Sturov, S. V. Popov, N. K. Mamporia & A. A. Mager. (2020) Urinary tract infections in patients with type 2 diabetes mellitus with pharmacological glucosuria. Terapevticheskii arkhiv 92:11, pages 106-109.
Crossref
Crossref
André J. Scheen. (2020) Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Reviews Endocrinology 16:10, pages 556-577.
Crossref
Crossref
Salvatore Carbone & Dave L. Dixon. (2019) The CANVAS Program: implications of canagliflozin on reducing cardiovascular risk in patients with type 2 diabetes mellitus. Cardiovascular Diabetology 18:1.
Crossref
Crossref
Janet B. McGill & Savitha Subramanian. (2019) Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. The American Journal of Cardiology 124, pages S45-S52.
Crossref
Crossref
Atsunori Kashiwagi, Marina V. Shestakova, Yuichiro Ito, Masahiro Noguchi, Wim Wilpshaar, Satoshi Yoshida & John P. H. Wilding. (2019) Safety of Ipragliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Phase II/III/IV Clinical Trials. Diabetes Therapy 10:6, pages 2201-2217.
Crossref
Crossref
Janet B. McGill & Savitha Subramanian. (2019) Safety of Sodium-Glucose Co-Transporter 2 Inhibitors. The American Journal of Medicine 132:10, pages S49-S57.e5.
Crossref
Crossref
Vishal Gupta, Michael Willis, Pierre Johansen, Andreas Nilsson, Manan Shah, Amey Mane & Cheryl Neslusan. (2019) Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. Value in Health Regional Issues 18, pages 65-73.
Crossref
Crossref
Vincent Woo, Alan Bell, Maureen Clement, Luis Noronha, Michael A. Tsoukas, Fernando Camacho, Shana Traina, Natasha Georgijev, Matthew D. Culham, Jennifer B. Rose, Wally Rapattoni & Harpreet S. Bajaj. (2018) CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice. Diabetes, Obesity and Metabolism 21:3, pages 691-699.
Crossref
Crossref
Young‐Gun Kim, Ja Young Jeon, Seung Jin Han, Dae Jung Kim, Kwan‐Woo Lee & Hae Jin Kim. (2018)
Sodium‐glucose co‐transporter‐2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus:
A
nationwide population‐based cohort study
. Diabetes, Obesity and Metabolism 20:8, pages 1852-1858.
Crossref
Crossref
André J. Scheen. (2018) Cardiovascular Effects of New Oral Glucose-Lowering Agents. Circulation Research 122:10, pages 1439-1459.
Crossref
Crossref
Serge Jabbour, Jochen Seufert, Andre Scheen, Clifford J. Bailey, Cathrina Karup & Anna M. Langkilde. (2017) Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials. Diabetes, Obesity and Metabolism 20:3, pages 620-628.
Crossref
Crossref
David Levy. 2018. Practical Diabetes Care. Practical Diabetes Care
49
76
.
Pravesh Kumar Bundhun, Girish Janoo & Feng Huang. (2017) Adverse drug events observed in patients with type 2 diabetes mellitus treated with 100 mg versus 300 mg canagliflozin: a systematic review and meta-analysis of published randomized controlled trials. BMC Pharmacology and Toxicology 18:1.
Crossref
Crossref
Girish N. Nadkarni, Rocco Ferrandino, Alexander Chang, Aditya Surapaneni, Kinsuk Chauhan, Priti Poojary, Aparna Saha, Bart Ferket, Morgan E. Grams & Steven G. Coca. (2017) Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis. Diabetes Care 40:11, pages 1479-1485.
Crossref
Crossref
Mohamed Hassanein, Akram Echtay, Ahmed Hassoun, Monira Alarouj, Bachar Afandi, Raffi Poladian, Abdullah Bennakhi, Maciej Nazar, Paul Bergmans, Sofia Keim, Gill Hamilton & Sami T. Azar. (2017) Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS). International Journal of Clinical Practice 71:10, pages e12991.
Crossref
Crossref
Emma D. Deeks & André J. Scheen. (2017) Canagliflozin: A Review in Type 2 Diabetes. Drugs 77:14, pages 1577-1592.
Crossref
Crossref
Mihoko Matsumura, Yuki Nakatani, Seiichi Tanka, Chie Aoki, Masaaki Sagara, Kazunori Yanagi, Kunihiro Suzuki & Yoshimasa Aso. (2017) Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM). Diabetes Therapy 8:4, pages 821-827.
Crossref
Crossref
Mehul Desai, Yshai Yavin, Dainius Balis, Don Sun, John Xie, William Canovatchel & Norm Rosenthal. (2017) Renal safety of canagliflozin, a sodium glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism 19:6, pages 897-900.
Crossref
Crossref
Matthew J. Budoff & John P. H. Wilding. (2017) Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus. International Journal of Clinical Practice 71:5, pages e12948.
Crossref
Crossref
Meg J. Jardine, Kenneth W. Mahaffey, Bruce Neal, Rajiv Agarwal, George L. Bakris, Barry M. Brenner, Scott Bull, Christopher P. Cannon, David M. Charytan, Dick de Zeeuw, Robert Edwards, Tom Greene, Hiddo J.L. Heerspink, Adeera Levin, Carol Pollock, David C. Wheeler, John Xie, Hong Zhang, Bernard Zinman, Mehul Desai & Vlado Perkovic. (2017) The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics. American Journal of Nephrology 46:6, pages 462-472.
Crossref
Crossref